|
Friday, October 4, 2013 | 8:30 AM - 4:30 PM
Speakers: David Artis (University of Pennsylvania), Stephen M. Collins (McMaster University), Michael A. Fischbach (University of California, San Francisco), Dirk Gevers (The Broad Institute of MIT and Harvard), Jeremy K. Nicholson (Imperial College London), Lita M. Proctor (National Human Genome Research Institute, NIH)
Symbioses between humans and our gut microbiome influence human biology including nutrition, immune function, and brain development. We review how symbiotic relationships impact drug metabolism and development, and a variety of disease states.
-
Thursday, June 20, 2013 | 11:30 AM - 3:00 PM
Speakers: Joel Kirman, MChE and Hugh L. Evans, PhD
The Lyceum Society comprises the Academy's retired and semi-retired members. Talks cover various scientific fields. All Academy members are welcome.
Monday, June 24, 2013 | 10:30 AM - 3:00 PM
Speakers: Yasmine Belkaid (National Institute of Allergy and Infectious Diseases, NIH), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Memorial Sloan-Kettering Cancer Center)
The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.
Wednesday, June 26, 2013 | 7:00 PM - 8:30 PM
Louis N. Sorkin, Entomologist at the American Museum of Natural History
A recent UN Food and Agriculture Organization report proposes that entomophagy—insect eating—is a healthy and sustainable way to provide the world's population with protein. Join us as we learn all about what bugs make a tasty treat and sample some yourself!
Wednesday, September 18, 2013 | 5:00 PM - 6:45 PM
Moderator: Orla M. Smith (Science Translational Medicine)
Panelists: Amanda Boxtel (Ekso Bionics), Grégoire Courtine (Swiss Federal Institute of Technology, EPFL), Nathan Harding (Ekso Bionics)
Join us for a discussion of cutting-edge technologies that may revolutionize spinal cord injury rehabilitation and treatment. Included in the discussion is a live demonstration of a wearable robot (or exoskeleton) that enables people with lower-extremity paralysis or weakness to stand and walk. We will present perspectives from an innovator, a researcher, and a patient, who will share their insights on how these new technologies benefit the public now and in the future to come.
September 18 - 20, 2013
Explore innovative models for advancing the translation of novel neurotechnologies, such as neurostimulation, brain-computer interfaces, and neuron replacement therapies, into diagnostic tools and treatments for neurological and psychiatric disease.
Tuesday, September 24, 2013 | 8:30 AM - 4:30 PM
Speakers: Karin Bornfeldt (University of Washington School of Medicine), Elena V. Galkina (Eastern Virginia Medical School), Emmanuel L. Gautier (Washington University School of Medicine, St. Louis), Klaus Ley (La Jolla Institute for Allergy and Immunology), Andrew H. Lichtman (Brigham and Women's Hospital, Harvard Medical School), Kathryn J. Moore (New York University Medical Center), Matthias Nahrendorf (Harvard Medical School), Alan R. Tall (Columbia University Medical Center)
Currently available therapies fail to resolve the full burden of many cardiovascular diseases. Understanding the role of key hematopoietic and inflammatory players in this disease process may help identify new targets for fighting atherosclerosis.
Friday, October 4, 2013 | 8:30 AM - 4:30 PM
Speakers: David Artis (University of Pennsylvania), Stephen M. Collins (McMaster University), Michael A. Fischbach (University of California, San Francisco), Dirk Gevers (The Broad Institute of MIT and Harvard), Jeremy K. Nicholson (Imperial College London), Lita M. Proctor (National Human Genome Research Institute, NIH)
Symbioses between humans and our gut microbiome influence human biology including nutrition, immune function, and brain development. We review how symbiotic relationships impact drug metabolism and development, and a variety of disease states. This symposium features a poster session.
Tuesday, October 22, 2013 | 8:30 AM - 4:30 PM
Speakers: Yasmina Bauer (Actelion Pharmaceuticals Ltd), Jeremy S. Duffield (University of Washington), Raghu Kalluri (The University of Texas MD Anderson Cancer Center), Marco Prunotto (F. Hoffmann-La Roche), Richard M. Silver (Medical University of South Carolina), Dianqing (Dan) Wu (Yale University)
Fibrosis is common in chronic organ injury, leading to progressive life-threatening outcomes. We review the link between fibrosis and disease and explore ways to use biomarkers and imaging to translate laboratory results into clinical success.
Thursday, October 24, 2013 | 8:30 AM - 7:00 PM
Explore emerging basic and translational research that impacts our understanding of Parkinson's Disease and its treatment.
Monday, November 4, 2013 | 8:30 AM - 4:30 PM
Speakers: Anirban Banerjee (National Institute of Child Health and Human Development, NIH), Carole A. Bewley (National Institute of Diabetes and Digestive and Kidney Diseases, NIH), Bryan Fry (The University of Queensland, Australia), Mandë Holford (Hunter College, CUNY / American Museum of Natural History), Baldomero M. Olivera (University of Utah), Beatrix Ueberheide (New York University)
Spiders, snakes, scorpions, sea snails and leeches produce over 10 million compounds offering great potential for venom-based drug discovery. This symposium investigates genomic, proteomic, and transcriptomic approaches to harness venom compounds.
November 6 - 7, 2013
NIA Technical Advisor: Neil Buckholtz (National Institute on Aging)
Organizers: Alan Cross (AstraZeneca), Sonya Dougal (formerly at The New York Academy of Sciences), Howard Feldman (University of British Columbia), Surya Kolluri (Bank of America), Ian Kremer (Leaders Engaged on Alzheimer's Disease), Tetsuyuki Maruyama (Takeda), Richard C. Mohs (Eli Lilly and Company), Jeffrey S. Nye (Janssen R&D), Ronald C. Petersen (Mayo Clinic), Gregory A. Petsko (Weill Cornell Medical College), Andrea Pfeifer (AC Immune), Thomas Rooney (Sanofi), Darryle D. Schoepp (Merck and Company, Inc.), Diane Stephenson (Critical Path Institute), Rudolph E. Tanzi (Harvard Medical School), John Q. Trojanowski (University of Pennsylvania), Diana L. van de Hoef (The New York Academy of Sciences), George Vradenburg (The Global CEO Initiative on Alzheimer's Disease), Michael Weiner (University of California, San Francisco)
This conference will convene leading industry, academic, and government stakeholders to discuss how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer our current drug development and evaluation systems, and identify innovative technologies and financing models. The outcome of this meeting will comprise a research agenda that will delineate the pathways needed to effectively treat and prevent Alzheimer's disease by 2025.
Tuesday, December 10, 2013 | 8:30 AM - 4:30 PM
Speakers: Frank M. LaFerla (University of California, Irvine), Sylvain E. Lesné (University of Minnesota), Bingwei Lu (Stanford University School of Medicine), Lennart Mucke (Gladstone Institute of Neurological Disease), Ralph A. Nixon (Nathan Kline Institute), Franck Polleux (The Scripps Research Institute), Terrence Town (University of Southern California), Tony Wyss-Coray (Stanford University School of Medicine)
Organizers: Ken Jones (Forest Research Institute), Robert Martone (Covance Biomarker Center of Excellence),
Robert B. Nelson (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)
This symposium explores how efforts to better integrate our understanding of neuritic plaques and neurofibrillary tangles—the two hallmark pathologies of Alzheimer's disease—are leading to a 'truce' between former rivals in the quest for therapies.
|
|